For example, in the Treat-CTC (NCT01548677) Phase II RCT, the investigators are investigating the correlation between CTCs and disease survival in patients with human epidermal growth factor receptor 2 (HER2) negative primary breast cancer treated with trastuzumab therapy. This evidence concerns the gene ERBB2 and breast carcinoma.